Centrexion

    OverviewSuggest Edit

    Centrexion Therapeutics is focused on developing new therapies for moderate to severe chronic pain that address the safety and efficacy gaps in the current treatment paradigm. We aim to relieve the suffering associated with chronic pain by creating treatments that address the safety and efficacy gaps in the current treatment paradigm.
    TypePublic
    Founded2013
    HQBoston, MA, US
    Websitecentrexion.com

    Latest Updates

    Employees (est.) (Oct 2018)27(+4%)
    Share Price (Feb 2019)$2
    Cybersecurity ratingAMore

    Key People/Management at Centrexion

    Jeffrey B. Kindler

    Jeffrey B. Kindler

    CEO
    James N. Campbell

    James N. Campbell

    President, Chief Scientific Officer
    Randall Stevens

    Randall Stevens

    Chief Medical Officer
    Mike Ward

    Mike Ward

    Chief Financial Officer
    Kimberly Guedes

    Kimberly Guedes

    Vice President, Clinical Operations
    Colleen Newman

    Colleen Newman

    Vice President, Head of Clinical Operations
    Show more

    Centrexion Office Locations

    Centrexion has offices in Boston and Baltimore
    Boston, MA, US (HQ)
    200 State St 6th Floor
    Baltimore, MD, US
    509 S Exeter St #202
    Show all (2)

    Centrexion Financials and Metrics

    Centrexion Revenue

    USD

    Net income (FY, 2017)

    (24.7m)

    EBIT (FY, 2017)

    (24.1m)

    Cash (30-Sept-2018)

    42.1m
    USDFY, 2016FY, 2017

    General and administrative expense

    5.4m6.4m

    R&D expense

    27.8m17.6m

    Operating expense total

    33.2m24.1m

    EBIT

    (33.2m)(24.1m)
    Annual
    USDFY, 2016FY, 2017

    Cash

    16.2m60.7m

    Prepaid Expenses

    827.0k665.0k

    Current Assets

    17.1m61.3m

    PP&E

    60.0k29.0k
    Quarterly
    USDQ3, 2018

    Cash

    42.1m

    Prepaid Expenses

    3.8m

    Current Assets

    45.9m

    PP&E

    23.0k
    Annual
    USDFY, 2016FY, 2017

    Net Income

    (37.7m)(24.6m)

    Depreciation and Amortization

    36.0k21.0k

    Accounts Payable

    1.0m358.0k

    Cash From Operating Activities

    (30.6m)(22.3m)
    Quarterly
    USDQ3, 2018Q3, 2019

    Net Income

    (19.5m)(25.3m)

    Depreciation and Amortization

    19.0k6.0k

    Accounts Payable

    1.9m1.2m

    Cash From Operating Activities

    (16.8m)(24.3m)
    USDFY, 2016

    Financial Leverage

    1.8 x
    Show all financial metrics

    Centrexion Cybersecurity Score

    Cybersecurity ratingPremium dataset

    A

    96/100

    SecurityScorecard logo

    Centrexion Online and Social Media Presence

    Embed Graph

    Centrexion Company Culture

    • CEO Rating

      A+

      100/100

    • Compensation

      D

      55/100

    Learn more on Comparably

    Centrexion News and Updates

    Centrexion Therapeutics Raises $40.5 Million and Adds Lilly and Exome Asset Management as New Investors

    BOSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Centrexion Therapeutics Corporation, a biotechnology company focused on developing and commercializing non-opioid, non-addictive chronic pain drugs and in-licensing undervalued mid-stage drug candidates across multiple target therapeutic areas, today annou…

    Centrexion Therapeutics to Announce CNTX-4975 Trial Results at the European League Against Rheumatism’s (EULAR) 2019 Annual European Congress of Rheumatology

    BOSTON, June 11, 2019 (GLOBE NEWSWIRE) -- Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-addictive therapeutics for the treatment of chronic pain, today announced that it will report data from two clinical studies of CNTX-4975, including an assessment of the c…

    Centrexion Therapeutics Announces Completion of Patient Enrollment in Pivotal Clinical Trial of Repeat Doses of CNTX-4975 in Patients with Moderate to Severe Osteoarthritis Knee Pain

    BOSTON, June 05, 2019 (GLOBE NEWSWIRE) -- Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-addictive therapeutics for the treatment of chronic pain, today announced completion of patient enrollment in its second pivotal trial, VICTORY-2, a randomized, double-bli…

    Lilly Announces Licensing Agreement for Non-Opioid Pain Asset from Centrexion Therapeutics

    INDIANAPOLIS, May 28, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a license agreement to acquire the exclusive worldwide rights for CNTX-0290 from Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-addictive therapeutics for the ...

    Centrexion Therapeutics Announces CNTX-4975 Preclinical and Clinical Data Presentations at the 35th Annual American Academy of Pain Medicine Meeting

    Company will present two posters on CNTX-4975 for treatment of moderate to severe knee osteoarthritis pain;pharmacological data from preclinical and Phase 1 and 2 clinical trials describing the mechanism of action; and efficacy,safety and pharmacokinetic profile from late-stage clinical trials

    Centrexion Therapeutics Announces Completion of Patient Enrollment in Pivotal Phase 3 Clinical Trial of CNTX-4975 for the Treatment of Moderate to Severe Knee Osteoarthritis Pain

    BOSTON, Dec. 05, 2018 (GLOBE NEWSWIRE) -- Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-addictive therapeutics for the treatment of chronic pain, today announced completion of patient enrollment ahead of schedule in its pivotal Phase 3 VICTORY-1 trial, a rand…
    Show more

    Centrexion Blogs

    Centrexion Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Lead Pipeline Candidate CNTX-4975

    The post Centrexion Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Lead Pipeline Candidate CNTX-4975 appeared first on Centrexion.

    Centrexion Therapeutics Announces CNTX-4975 Data Presentations at the 2019 American College of Rheumatology Annual Meeting and the 2019 American Academy of Physical Medicine and Rehabilitation Annual Assembly

    The post Centrexion Therapeutics Announces CNTX-4975 Data Presentations at the 2019 American College of Rheumatology Annual Meeting and the 2019 American Academy of Physical Medicine and Rehabilitation Annual Assembly appeared first on Centrexion.

    Centrexion Therapeutics Announces Completion of Patient Enrollment in VICTORY-3 Phase 3 Open-Label Clinical Trial of CNTX-4975 in Patients with Moderate-to-Severe Osteoarthritis Knee Pain

    The post Centrexion Therapeutics Announces Completion of Patient Enrollment in VICTORY-3 Phase 3 Open-Label Clinical Trial of CNTX-4975 in Patients with Moderate-to-Severe Osteoarthritis Knee Pain appeared first on Centrexion.

    Centrexion Frequently Asked Questions

    • When was Centrexion founded?

      Centrexion was founded in 2013.

    • Who are Centrexion key executives?

      Centrexion's key executives are Jeffrey B. Kindler, James N. Campbell and Randall Stevens.

    • How many employees does Centrexion have?

      Centrexion has 27 employees.

    • Who are Centrexion competitors?

      Competitors of Centrexion include Servier, USV and Aurobindo Pharma.

    • Where is Centrexion headquarters?

      Centrexion headquarters is located at 200 State St 6th Floor, Boston.

    • Where are Centrexion offices?

      Centrexion has offices in Boston and Baltimore.

    • How many offices does Centrexion have?

      Centrexion has 2 offices.